Literature DB >> 17687350

China syndrome--a regulatory framework in meltdown?

Hepeng Jia.   

Abstract

Mesh:

Year:  2007        PMID: 17687350     DOI: 10.1038/nbt0807-835

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  4 in total

1.  Backlog cripples China's drug regulator.

Authors: 
Journal:  Nat Biotechnol       Date:  2015-06       Impact factor: 54.908

2.  China overhauls drug regulation agency.

Authors:  Hepeng Jia
Journal:  Nat Biotechnol       Date:  2013-05       Impact factor: 54.908

3.  Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?

Authors:  Jay D Naik; Christopher J Twelves; Peter J Selby; Richard G Vile; John D Chester
Journal:  Clin Cancer Res       Date:  2011-05-16       Impact factor: 12.531

Review 4.  Chinese health biotech and the billion-patient market.

Authors:  Sarah E Frew; Stephen M Sammut; Alysha F Shore; Joshua K Ramjist; Sara Al-Bader; Rahim Rezaie; Abdallah S Daar; Peter A Singer
Journal:  Nat Biotechnol       Date:  2008-01       Impact factor: 54.908

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.